These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35554915)

  • 21. The Undiscovered Potential of Essential Oils for Treating SARS-CoV-2 (COVID-19).
    Wilkin PJ; Al-Yozbaki M; George A; Gupta GK; Wilson CM
    Curr Pharm Des; 2020; 26(41):5261-5277. PubMed ID: 33059564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of potential therapeutic agents to treat COVID-19.
    Dong X; Tian Z; Shen C; Zhao C
    Biosci Trends; 2020 Nov; 14(5):318-327. PubMed ID: 33100290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced microscopy technologies enable rapid response to SARS-CoV-2 pandemic.
    Cortese M; Laketa V
    Cell Microbiol; 2021 Jul; 23(7):e13319. PubMed ID: 33595881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovering small-molecule therapeutics against SARS-CoV-2.
    Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
    Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research.
    Ray S; Srivastava S
    OMICS; 2020 Aug; 24(8):457-459. PubMed ID: 32427517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19.
    Rahman MM; Ahmed M; Islam MT; Khan MR; Sultana S; Maeesa SK; Hasan S; Hossain MA; Ferdous KS; Mathew B; Rauf A; Uddin MS
    Curr Pharm Des; 2022; 28(12):948-968. PubMed ID: 34218774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
    Narayanan D; Parimon T
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
    Das AB
    BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential of algal metabolites for the development of broad-spectrum antiviral therapeutics: Possible implications in COVID-19 therapy.
    Sangtani R; Ghosh A; Jha HC; Parmar HS; Bala K
    Phytother Res; 2021 May; 35(5):2296-2316. PubMed ID: 33210447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses.
    Napolitano V; Dabrowska A; Schorpp K; Mourão A; Barreto-Duran E; Benedyk M; Botwina P; Brandner S; Bostock M; Chykunova Y; Czarna A; Dubin G; Fröhlich T; Hölscher M; Jedrysik M; Matsuda A; Owczarek K; Pachota M; Plettenburg O; Potempa J; Rothenaigner I; Schlauderer F; Slysz K; Szczepanski A; Greve-Isdahl Mohn K; Blomberg B; Sattler M; Hadian K; Popowicz GM; Pyrc K
    Cell Chem Biol; 2022 May; 29(5):774-784.e8. PubMed ID: 35021060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics.
    Liu D; Shameem M
    Ther Deliv; 2022 Feb; 13(2):67-69. PubMed ID: 34726506
    [No Abstract]   [Full Text] [Related]  

  • 34. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges.
    Xu X; Chen Y; Lu X; Zhang W; Fang W; Yuan L; Wang X
    Biochem Pharmacol; 2022 Nov; 205():115279. PubMed ID: 36209840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.
    Bhattacharyya P; Das S; Aich S; Sarkar J
    Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2.
    Wang SF; Chen KH; Wang SY; Yarmishyn AA; Lai WY; Lin YY; Wang ML; Chou SJ; Yang YP; Chang YL
    J Chin Med Assoc; 2020 Aug; 83(8):712-718. PubMed ID: 32433345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics.
    Kabra R; Singh S
    Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165978. PubMed ID: 32980462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.